

Venus Remedies clinches dual tender from UNICEF & PAHO to enhance healthcare access

20 June 2024 | News

The orders will continue to strengthen the company's international presence



Three months after getting the coveted Good Manufacturing Practices (GMP) approval from the United Nations International Children's Emergency Fund (UNICEF), Panchkula-based pharmaceutical company Venus Remedies has been awarded a tender by UNICEF for supplying ceftriaxone (1gm), a beta-lactam antibiotic, in dry powder form.

Ceftriaxone dry powder is an important drug in Venus Remedies' extensive antibiotic portfolio. Moreover, ceftriaxone is an important antibiotic globally due to its broad-spectrum activity and effectiveness in treating a variety of serious bacterial infections.

The global ceftriaxone market was valued at \$1.7 billion in 2021 and is expected to grow at a CAGR of 2.9% from 2022 to 2031 to reach over \$2.2 billion by the end of 2031.

In another development crucial to improving healthcare outcomes in Latin America, Venus Remedies has been awarded an oncology tender by the WHO-backed Pan American Health Organisation (PAHO), the world's oldest international public health agency.

The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs like bleomycin, carboplatin, cisplatin, cytarabine, doxorubicin, irinotecan, methotrexate and vincristine.